Alemtuzumab-related thyroid disease in people with multiple sclerosis is associated with age and brainstem phenotype at disease onset

Background Autoimmune thyroid disease (AITD) occurs in 40%–50% of alemtuzumab-treated persons with multiple sclerosis (pwMS), most of whom will develop Graves’ Disease (GD). Objective To explore contributory factors for alemtuzumab-related AITD in pwMS. Methods A retrospective patient chart review w...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Multiple sclerosis journal - experimental, translational and clinical translational and clinical, 2020-04, Vol.6 (2), p.2055217320933928-2055217320933928
Hauptverfasser:	Yap, Siew Mei, Dillon, Mary, Crowley, Rachel K, McGuigan, Christopher
Format:	Artikel
Sprache:	eng
Schlagworte:	Drug therapy Graves disease Immunotherapy Monoclonal antibodies Multiple sclerosis Original Research Paper Thyroid diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!